Inventor · disambiguated record
Christian Valdemar Vinge Leisner
Also filed as: LEISNER CHRISTIAN · LEISNER CHRISTIAN VALDEMAR VINGE
4 granted patents·9 pending applications·2 citations·filing 2017–2025
60Inventor score
Top patents by PatentIndex Score
13 records- 0187US11912771B2MAGE-A4 peptide-MHC antigen binding proteinsCDR LIFE AG·Filed 2022·Granted Feb 27, 2024·2 cites·30 claims
- 0275US2025243266A1Anti-c3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseasesCDR LIFE AG·Filed 2024·Application pending·0 cites
- 0372US12344663B2Anti-C3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseasesCDR LIFE AG·Filed 2022·Granted Jul 1, 2025·0 cites·94 claims
- 0470US2025129414A1Methods of treating dry eye disease using tnf alpha antagonistsNOVARTIS AG·Filed 2024·Application pending·0 cites
- 0567US12161673B2MAGE-A4 peptide dual T cell engagersCDR LIFE AG·Filed 2023·Granted Dec 10, 2024·0 cites·40 claims
- 0667US2024279344A1Mage-a4 peptide-mhc antigen binding proteinsCDR LIFE AG·Filed 2024·Application pending·0 cites
- 0766US2025144141A1Mage-a4 peptide dual t cell engagersCDR LIFE AG·Filed 2024·Application pending·0 cites
- 0860US2022259296A1Complement c3 antigen binding proteinsBOEHRINGER INGELHEIM INT·Filed 2022·Application pending·0 cites
- 0959US2025382357A1Complement c3 antigen binding proteinsBOEHRINGER INGELHEIM INT·Filed 2025·Application pending·0 cites
- 1055US12146187B2Methods of treating dry eye disease using TNF alpha antagonistsNOVARTIS AG·Filed 2017·Granted Nov 19, 2024·0 cites·4 claims
- 1152US2020024358A1Trispecific antigen binding proteinsCDR LIFE AG·Filed 2019·Application pending·0 cites
- 1251US2020062858A1Trispecific antigen binding proteinsCDR LIFE AG·Filed 2019·Application pending·0 cites
- 1344US2025333514A1Antigen binding proteins targeting an hla-restricted prame peptideCDR LIFE AG·Filed 2025·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Christian Valdemar Vinge Leisner files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →